selonsertib (GS-4997) / Gilead  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
selonsertib (GS-4997) / Gilead
ACTRN12618001377224: A Phase 1b, Randomized, Blinded, Placebo-Controlled Study to Evaluate the Effect of Selonsertib on Renal Function as Assessed by Markers of Glomerular Filtration Rate in Subjects with Chronic Kidney Disease

Recruiting
1
60
 
Gilead Sciences, Gilead Sciences
Chronic Kidney Disease
 
 
NCT02509624: Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

Completed
1
52
US
Selonsertib, GS-4997
Gilead Sciences
Diabetic Kidney Disease
12/15
12/15
NCT03087968: Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124

Withdrawn
1
0
US
GS-4997, Prednisolone, HepQuant SHUNT Test, SHUNT, Placebo
HepQuant, LLC
Severe Alcoholic Hepatitis
09/17
09/17

Download Options